Table 1.
Analysis of the association between expression of hsa-miR-4634 and clinicopathological features of NSCLC (n = 323).
| Clinicopathological features (n) | hsa-miR-4634 | ||
|---|---|---|---|
| Low expression (%) | High expression (%) | P-value | |
| Age (years) | |||
| ≤ 55 (n = 146) | 68 (46.6%) | 78 (53.4%) | 0.094 |
| > 55 (n = 177) | 99(55.9%) | 78 (44.1%) | |
| Gender | |||
| Male (n = 240) | 117 (48.8%) | 123 (51.3%) | 0.071 |
| Female (n = 83) | 50 (60.2%) | 33 (39.8%) | |
| Histological types | |||
| ADC (n = 162) | 88 (54.3%) | 74 (45.7%) | 0.345 |
| SCC (n = 161) | 79 (49.1%) | 82 (50.9%) | |
| LNM status | |||
| NO LNM (n = 128) | 57 (44.5%) | 71 (55.5%) | 0.037* |
| LNM (n = 195) | 110 (56.4%) | 85 (43.6%) | |
| Differentiation | |||
| Well/Moderate (n = 150) | 73 (48.7%) | 77 (51.3%) | 0.309 |
| Poor (n = 173) | 94 (54.3%) | 79 (45.7%) | |
| Clinical stages | |||
| Stage I and II (n = 167) | 84 (50.3%) | 83 (49.7%) | 0.602 |
| Stage III (n = 156) | 83 (53.2%) | 73 (46.8%) | |
| Survival status | |||
| Alive (n = 210) | 100 (47.6%) | 110 (52.4%) | 0.045* |
| Dead (n = 113) | 67 (59.3%) | 46 (40.7%) | |
*Chi-square test, statistically significant difference (*P < 0.05).
ADC adenocarcinoma, H high expression, L low expression, LNM lymph node metastasis, NSCLC non-small cell lung cancer, SCC squamous cell carcinoma.